Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to
placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular
and/or coronary artery bypass graft surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Astellas Pharma US, Inc. Cardiome Pharma Correvio International Sarl